1.3
Ensaios clínicos: visão geral
A pesquisa clínica concentra-se em como a droga interagirá com o corpo humano e abrange quatro fases-chave de ensaios clínicos, cada uma atendendo a u…
Os ensaios clínicos são estudos de pesquisa que avaliam as propriedades farmacológicas de um medicamento candidato em humanos. Esses ensaios são conduzidos em várias fases.
Na fase I, cinco a dez medicamentos candidatos de estudos pré-clínicos bem-sucedidos são testados em um pequeno grupo de indivíduos saudáveis ou pacientes para avaliar vários efeitos, como toxicidade potencial, efeitos colaterais, farmacocinética e farmacodinâmica.
Os candidatos bem-sucedidos da fase I são testados na fase II em cem a trezentos pacientes para monitorar a eficácia do medicamento e a regulação da dosagem.
Os candidatos que passam na triagem da fase II são testados na fase III quanto à sua segurança e eficácia. Os ensaios de fase III são estudos duplo-cegos conduzidos em milhares de pacientes em muitos centros.
Após um estudo de fase III bem-sucedido, um pedido de novo medicamento é submetido ao FDA para aprovação de comercialização.
Uma vez que o medicamento é aprovado pela FDA, o fabricante produz e coloca o medicamento no mercado.
A vigilância pós-comercialização, ou fase IV, é feita para estudar os efeitos adversos raros ou de longo prazo do medicamento.
View the full transcript and gain access to JoVE Core videos
Q1: What happens in phase I of a clinical trial?
Phase I tests five to ten candidate drugs on a small group of healthy individuals or patients to evaluate toxicity, side effects, pharmacokinetics, and pharmacodynamics. This initial phase determines whether the drug is safe enough to proceed to larger patient populations and establishes baseline tolerability and safety data for advancement.
Q2: How do phase II and phase III clinical trials differ?
Phase II expands testing to 100-300 patients to monitor drug efficacy and dosage regulation. Phase III involves double-blind, randomized trials with thousands of patients across multiple centers to comprehensively compare the new drug against existing alternatives or placebos, making it more costly and time-consuming than phase II.
Q3: What is the purpose of phase IV trials?
Phase IV, or postmarketing surveillance, monitors long-term and rare adverse effects in large patient populations after FDA approval. This ongoing phase ensures drug safety continues to be tracked throughout its use in the general population and identifies effects that may not appear in earlier trial phases.
Q4: What happens after a successful phase III trial?
After phase III success, a New Drug Application is submitted to the FDA with a detailed dossier of preclinical and clinical data. The FDA reviews the submission, and approval can take a year or longer, with approximately two-thirds of submissions receiving marketing approval for commercial distribution.
Q5: How long does the entire drug development process take?
The complete drug development process, including clinical trials, spans 7 to 12 years. This extended timeline reflects the rigorous testing required across preclinical development overview phases, multiple clinical trial phases, and regulatory review before a drug reaches the market for patient use.
Q6: What standards must clinical trials follow?
Clinical trials must adhere to Good Clinical Practice guidelines, ensuring meticulous patient group selection, data collection, statistical analysis, and documentation. Phase III trials increasingly incorporate pharmacoeconomic analysis to assess both clinical and economic benefits of new drugs before regulatory submission and approval.
Q7: What determines whether a drug candidate advances from phase I testing?
Successful candidates from phase I demonstrate acceptable safety profiles and provide data on pharmacokinetics and pharmacodynamics. Only drugs showing sufficient tolerability and lack of prohibitive toxicity advance to phase II testing in larger patient groups to evaluate therapeutic efficacy and optimal dosage.